Disease progression and pharmacodynamics in Parkinson disease - evidence for functional protection with levodopa and other treatments.

Journal of Pharmacokinetics and Pharmacodynamics
Nicholas H G HolfordParkinson Study Group

Abstract

We have modelled the Unified Parkinson's Disease Rating Scale (UPDRS) scores collected in 800 subjects followed for 8 years. Newly diagnosed and previously untreated subjects were initially randomized to treatment with placebo, deprenyl, tocopherol or both and, when clinical disability required, received one or more dopaminergic agents (levodopa (carbidopa/levodopa), bromocriptine, or pergolide). Using models for disease progression and pharmacodynamic models for drug effects we have characterized the changes in UPDRS over time to determine the influence of the various drug treatments. We have confirmed and quantitated the relative symptomatic benefits of the dopaminergic agents and provide model-based evidence for slowing of disease progression.

References

Dec 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·N H Holford, K E Peace
Nov 16, 1989·The New England Journal of Medicine·UNKNOWN Parkinson Study Group
Feb 1, 1981·Neurology·C H Markham, S G Diamond
Nov 1, 1995·Annals of Neurology·C W OlanowJ Esterlitz
Jan 21, 1993·The New England Journal of Medicine·UNKNOWN Parkinson Study Group
Dec 1, 1996·Neurology·S Fahn
Mar 1, 1997·Clinical Pharmacology and Therapeutics·L B Sheiner
Dec 20, 1999·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·M G MurerO Gershanik
Jun 3, 2000·Annual Review of Pharmacology and Toxicology·N H HolfordC C Peck
Oct 14, 2000·Journal of Neurology, Neurosurgery, and Psychiatry·C E Clarke, P Davies
Oct 18, 2000·JAMA : the Journal of the American Medical Association·UNKNOWN Parkinson Study Group
Mar 27, 2001·Annual Review of Pharmacology and Toxicology·P L Chan, N H Holford
Apr 3, 2002·JAMA : the Journal of the American Medical Association·UNKNOWN Parkinson Study Group
Jul 12, 2002·Annals of Neurology·John G NuttGary J Sexton
Oct 3, 2002·Movement Disorders : Official Journal of the Movement Disorder Society·Robert A Hauser, Nicholas H G Holford
May 6, 2003·Journal of Biopharmaceutical Statistics·Craig H MallinckrodtGeert Molenbergh
Jun 13, 2003·Journal of Pharmacokinetics and Pharmacodynamics·Chuanpu Hu, Mark E Sale
Jul 3, 2003·Annals of Neurology·Alan L WhoneUNKNOWN REAL-PET Study Group
Sep 25, 2003·Neurology·A H V Schapira
Apr 21, 2004·Archives of Neurology·UNKNOWN Parkinson Study Group
Dec 14, 2004·The New England Journal of Medicine·Stanley FahnUNKNOWN Parkinson Study Group
Dec 2, 2005·Journal of Pharmacokinetics and Pharmacodynamics·Phylinda L S ChanNicholas H G Holford

❮ Previous
Next ❯

Citations

Dec 20, 2007·European Journal of Clinical Pharmacology·Nick Holford, John G Nutt
Jan 17, 2008·Journal of Pharmacokinetics and Pharmacodynamics·Teun M PostMeindert Danhof
Mar 6, 2010·Journal of Pharmacokinetics and Pharmacodynamics·Philippe JacqminJanet R Wade
Apr 18, 2013·Journal of Pharmacokinetics and Pharmacodynamics·Nick Holford
Feb 20, 2007·Pharmaceutical Research·Phylinda L S ChanNicholas H G Holford
Oct 15, 2008·Annual Review of Pharmacology and Toxicology·Jogarao V S Gobburu, Lawrence J Lesko
Jun 13, 2009·The AAPS Journal·Venkatesh Atul BhattaramJogarao V S Gobburu
Apr 24, 2014·Drugs·Matthias LöhleAnthony H V Schapira
May 30, 2013·British Journal of Clinical Pharmacology·Nick Holford
Sep 11, 2008·Movement Disorders : Official Journal of the Movement Disorder Society·John G Nutt
Feb 28, 2009·Journal of Clinical Pharmacology·Stefanie HennigMats O Karlsson
Jan 31, 2012·British Journal of Clinical Pharmacology·Thuy C VuNicholas H G Holford
Jul 28, 2013·CPT: Pharmacometrics & Systems Pharmacology·Nick Holford
Jun 23, 2011·British Journal of Clinical Pharmacology·David TernantGilles Paintaud
Apr 8, 2011·Statistics in Medicine·Matthew M HutmacherSujatha Menon
Jul 28, 2013·CPT: Pharmacometrics & Systems Pharmacology·K E KarlssonM O Karlsson
Apr 16, 2011·Movement Disorders : Official Journal of the Movement Disorder Society·Carl E ClarkeRichard Gray
Sep 20, 2012·British Journal of Clinical Pharmacology·Nicholas H G HolfordJohn G Nutt
Mar 4, 2011·Movement Disorders : Official Journal of the Movement Disorder Society·Nick H G Holford, John G Nutt
May 3, 2011·Parkinsonism & Related Disorders·Elise Anderson, John Nutt
May 27, 2016·Movement Disorders : Official Journal of the Movement Disorder Society·Charles S VenutoKarl Kieburtz
May 26, 2017·Annals of Neurology·Roger L Albin, Daniel K Leventhal
Nov 23, 2018·Journal of Neurology, Neurosurgery, and Psychiatry·Michael LawtonMichele T M Hu
Apr 5, 2008·Clinical Pharmacology and Therapeutics·R R BiesS L Schwartz
Jan 2, 2009·Movement Disorders : Official Journal of the Movement Disorder Society·Robert G HartJohn R Marler
Mar 14, 2008·Clinical Pharmacokinetics·Michel TodGérard Pons
Nov 26, 2009·Clinical Neuropharmacology·Yoshikuni MizunoNobuo Yanagisawa
Jul 9, 2010·Clinical Pharmacology and Therapeutics·N HolfordB A Ploeger
Dec 14, 2011·Pharmaceutical Statistics·Carl-Fredrik Burman, Stig Johan Wiklund
Jun 21, 2011·Applied Health Economics and Health Policy·James ShearerJohn P Zajicek
Feb 27, 2017·Clinical Pharmacokinetics·Aravind MitturNishit B Modi
Feb 26, 2020·Translational and Clinical Pharmacology·Nick Holford
Mar 2, 2017·The AAPS Journal·Gopichand GottipatiElodie L Plan
Sep 25, 2017·Current Pharmacology Reports·Sarah F Cook, Robert R Bies
Nov 23, 2017·Frontiers in Neurology·Alba AyalaPablo Martínez-Martín
Jun 2, 2020·Frontiers in Neurology·Kevin J BlackJonathan M Koller

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.